Trial · NCT04828993
Adverse events54
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 54
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 2 | 15 | |
| other | Coagulopathy | Blood and lymphatic system disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | Leukopenia | Blood and lymphatic system disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | Palpitations | Cardiac disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | Supraventricular extrasystoles | Cardiac disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | Supraventricular tachycardia | Cardiac disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | Cataract | Eye disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | Abdominal discomfort | Gastrointestinal disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | Abdominal pain | Gastrointestinal disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | Constipation | Gastrointestinal disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | Diarrhoea | Gastrointestinal disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 2 | 15 | |
| other | Nausea | Gastrointestinal disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | Vomiting | Gastrointestinal disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | Oedema peripheral | General disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | Hyperbilirubinaemia | Hepatobiliary disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | Hypersensitivity | Immune system disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | Seasonal allergy | Immune system disorders | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | COVID-19 | Infections and infestations | Tafamidis Meglumine 20 mg Once Daily (QD) | 1 | 15 | |
| other | Upper respiratory tract infection | Infections and infestations | Tafamidis Meglumine 20 mg Once Daily (QD) | 3 | 15 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04828993/events